The available evidence supports the idea that cannabinoids, which may have limited therapeutic value due to significant adverse reactions. May be beneficial as adjunctive agents in the management of mood disorders. Cannabinoids may increase or decrease the effects of some antidepressants.
A study, conducted at the Department of Applied Pharmacy at the Medical University of Lublin, Poland. (click here to view the study).
Combination therapy, which is superior to monotherapy in terms of efficacy, generally requires lower doses of individual components.
Therefore, the main objective of this study was to determine whether administration of cannabinoid (CB) receptor ligands would increase the antidepressant activity of the atypical antidepressants agomelatine and tianeptine.
The results suggest more than positive feedback
In summary, the results of the present study showed that activation and inhibition of CB1 receptors, as well as inhibition of CB2 receptors, can increase the antidepressant activity of tianeptine, only inhibition of CB1 and CB2 receptors has the potential to increase the antidepressant activity of agomelatine.